戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rmophilus does not affect its sensitivity to capreomycin.
2 esistance to the tuberactinomycin antibiotic capreomycin.
3 vity to tuberactinomycin antibiotics such as capreomycin.
4 increasing area under curve for amikacin and capreomycin.
5 odification that underpin Mtb sensitivity to capreomycin.
6  to 2 mug/ml), kanamycin (0.25 to 2 mug/ml), capreomycin (0.5 to 4 mug/ml), linezolid (0.25 to 2 mug/
7 ed susceptibility for phleomycin, bleomycin, capreomycin, amikacin, kanamycin, cetylpyridinium chlori
8 th despite treatment with a regimen based on capreomycin, aminosalicylic acid, or both).
9 , rrs and eis promoter (kanamycin), and rrs (capreomycin and amikacin).
10  the eis promoter for kanamycin; and rrs for capreomycin and amikacin.
11 amide, levofloxacin, moxifloxacin, amikacin, capreomycin and kanamycin resistance produced similar se
12 zed to tuberactinomycin antibiotics, such as capreomycin and viomycin, due to the action of the intri
13  and 84.1% for kanamycin, 54.3% and 100% for capreomycin, and 79.2% and 100% for amikacin, respective
14  and 100% for kanamycin, 93.9% and 97.4% for capreomycin, and 80% and 100% for amikacin.
15 r levofloxacin, 100% for amikacin, 97.4% for capreomycin, and 88.9% for ethionamide.
16 moxifloxacin), 99.2% for amikacin, 99.2% for capreomycin, and 96.4% for kanamycin.
17 r drugs studied were levofloxacin, amikacin, capreomycin, and ethionamide.
18 in, and kanamycin and the cyclic polypeptide capreomycin are all widely used in second-line therapy f
19 e, and at least 1 of amikacin, kanamycin, or capreomycin based on drug susceptibility test results fr
20                                      Optimal capreomycin binding and Mtb ribosome inhibition requires
21 he H69 tip, allosterically reconfiguring the capreomycin binding site.
22 option of a more open conformation to enable capreomycin binding.
23 H, FLQ, amikacin (AMK), kanamycin (KAN), and capreomycin (CAP) resistance, meeting the WHO target pro
24  (OFX), amikacin (AMK), kanamycin (KAN), and capreomycin (CAP) using MGIT 960 and WHO-recommended cri
25 berculostatic macrocyclic peptide antibiotic capreomycin IB has been accomplished.
26                                              Capreomycin is a potent ribosome-targeting antibiotic th
27 <=1.0), amikacin (<=2.0), kanamycin (<=8.0), capreomycin (&lt;=4.0), clofazimine (<=0.25) and linezolid
28 reptomycin, ethambutol, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxacin, ethionamide, para-
29 hambutol, streptomycin, amikacin, kanamycin, capreomycin, ofloxacin, moxifloxacin, ethionamide, para-
30 ing Mtb gene tlyA, which cause resistance to capreomycin, our current structural and mechanistic unde
31 of 16S rRNA, the site of previously reported capreomycin resistance base substitutions.
32                                              Capreomycin resistance in other bacteria has been shown
33       A spontaneous kanamycin resistance and capreomycin resistance mutation, A1408G, in the decoding
34 8% for amikacin, moxifloxacin, ofloxacin and capreomycin, respectively, as well increasing area under
35 losis drugs tested, 11 were monoresistant to capreomycin, rifampin, isoniazid (INH), pyrazinamide, or
36        Despite the important role of TlyA in capreomycin sensitivity and identification of inactivati
37 4-98.1]; specificity 98.6% [98.3-98.9]), and capreomycin (sensitivity 93.1% [90.0-96.3]; specificity
38 ch their isolate was susceptible, especially capreomycin sulfate, and among patients with a CD4+ T-ly
39 acin was 1.5 microg/ml, that established for capreomycin was 3.0 microg/ml, and that established for
40 A2137 and C2138) such that interactions with capreomycin would be lost and the binding pocket partial